{"id":437718,"date":"2019-10-14T12:06:01","date_gmt":"2019-10-14T12:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=437718"},"modified":"2019-10-14T12:06:01","modified_gmt":"2019-10-14T12:06:01","slug":"platinum-based-cancer-drugs-market-size-is-projected-to-reach-usd-18141-million-by-2026-polaris-market-research","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/platinum-based-cancer-drugs-market-size-is-projected-to-reach-usd-18141-million-by-2026-polaris-market-research_437718.html","title":{"rendered":"Platinum Based Cancer Drugs Market Size Is Projected To Reach USD 1,814.1 Million by 2026 | Polaris Market Research"},"content":{"rendered":"
\"Platinum<\/a><\/p>\n
\n
Polaris Market Research<\/div>\n<\/div>\n<\/div>\n
The global platinum based Cancer drugs market size was valued at USD 1,310.3 Million in 2018 and is expected to exhibit a CAGR of 4.1% from 2019 – 2026 according to a report published by Polaris Market Research<\/div>\n

The global Platinum Based Cancer Drugs Market<\/a> size is expected to reach USD 1,814.1 Million by 2026 according to a new study by Polaris Market Research. The report “Global Platinum Based Cancer Drugs Market Share, Size, Trends, Industry Analysis Report By Drug Type (Cisplatin, Oxaliplatin, Carboplatin, Other), Application (Colorectal, Ovarian, Lung, & Other Cancer); By Regions, Segments & Forecast, 2019 – 2026<\/strong><\/em>” gives a detailed insight into current market dynamics and provides analysis on future market growth.<\/p>\n

Drugs based on platinum have become a major component of cancer therapy; about half of all patients undergoing chemotherapy receive a platinum drug. The widespread use of platinum agents in cancer treatment started with Barnett Rosenberg’s discovery of cisplatin’s antineoplastic activity in the 1960s.<\/p>\n

Request A Sample Report At :<\/strong> https:\/\/www.polarismarketresearch.com\/industry-analysis\/platinum-based-cancer-drugs-market\/request-for-sample<\/a><\/p>\n

According to the National Cancer Institute, the instances of new cases per year is expected to rise to 23.6 million by 2030. Nevertheless, the major limitations of this industry worldwide are the drug-related side effects and resistance growth. Recent developments in platinum based cancer drugs include the development of analog platinum drugs such as platinum carrier molecule complexes to boost targeted concentration of drugs in cancer tumor. This increasing number of cancer instances is expected to drive the growth of the global platinum cancer drug market during the forecast period.<\/p>\n

                               \"Global<\/p>\n

The platinum based cancer drugs market can be categorized in terms of product type as oxaliplatin, cisplatin, carboplatin, and others. Cisplatin is the most commonly used for treating certain malignancies. It is particularly effective in testicular cancer and is intravenously administered. Carboplatin, a derivative of cisplatin, is used to treat multiple cancers like ovaries, lungs, brains, and so on. Cisplatin’s segment maintained the largest market share in 2018 and is expected to remain dominant over the forecast period. Based on application, the global market is divided into ovarian, lung, testicular, colorectal, and other cancer. The lung cancer segment dominated the market in 2018 due to the high incidence among the world’s population.<\/p>\n

Due to enhanced disease prevalence, enhanced awareness, increased per capita income, and enhanced health care infrastructure, the Asia Pacific market is anticipated to develop at the largest CAGR. North America dominated the global market in 2018 due to the high incidence of cancer in the region, developments in these drugs and recent FDA approvals. United States is the world’s largest drug market. This has led to the dominance of North America in the global platinum cancer drug market. The U.S. pharmaceutical industry is the largest domestic market in the world. It is the world’s biggest continental pharmaceutical market together with Canada and Mexico. More than 45 percent of the worldwide pharmaceutical industry is held by the United States alone. This share was valued at approximately $446 Million in 2016. Many of the top worldwide firms are from the U.S. In 2016, six out of the top 10 firms were based on sheer pharmaceutical income from the United States.<\/p>\n

Browse More Insight Of Platinum Based Cancer Drugs Market Research Report Enabled with Respective Tables and Figures at:<\/strong> https:\/\/www.polarismarketresearch.com\/industry-analysis\/platinum-based-cancer-drugs-market<\/a><\/p>\n

Major players in the platinum cancer drug market include Sanofi, Pfizer, Inc., Mylan N.V., Ask-Pharma, Sun Pharmaceutical Industries Ltd., Accord Healthcare, Novartis AG, Teva Pharmaceutical Industries Ltd., Guizhou YiBai Pharmaceutical Co., Ltd., SK Chemicals, Qilu Pharmaceutical Co., Ltd., Dr. Reddy’s Laboratories Ltd., Debiopharm Group, and Jiangsu Hengrui Pharmaceutical Co., Ltd.<\/p>\n

Polaris Market research has segmented the Platinum Based Cancer Drugs market report on the basis of drug type, application type, and region<\/strong><\/em><\/p>\n

Platinum Based Cancer Drug Type<\/strong><\/p>\n

Cisplatin
Oxaliplatin
Carboplatin
Other<\/p>\n

Platinum Based Cancer Drugs Application Type<\/strong><\/p>\n

Colorectal Cancer
Ovarian Cancer
Lung Cancer
Other<\/p>\n

Platinum Based Cancer Drugs Regional<\/strong><\/p>\n

North America (U.S., Canada)
Europe (UK, Germany, France, Italy, Russia)
Asia Pacific (China, India, Japan, South Korea)
Latin America (Brazil, Mexico, Colombia)
MEA (Saudi Arabia, South Africa, Israel, UAE)<\/p>\n

Leading Key Players of Platinum Based Cancer Drugs Market<\/strong><\/p>\n

Sanofi
Pfizer, Inc.
Mylan N.V
Ask-Pharma
Sun Pharmaceutical Industries Ltd
Accord Healthcare
Novartis AG
Teva Pharmaceutical Industries Ltd
Guizhou YiBai Pharmaceutical Co., Ltd
SK Chemicals<\/p>\n

Have Any Query Or Specific Requirement? Feel Free To Ask Our Industry Experts:<\/strong> https:\/\/www.polarismarketresearch.com\/industry-analysis\/platinum-based-cancer-drugs-market\/speak-to-analyst<\/a><\/p>\n

About Polaris Market Research<\/strong><\/p>\n

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Polaris Market Research and Consulting<\/a>
Contact Person:<\/strong> Mr.Likhil
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +1-646-568-9980
Address:<\/strong>30 Wall Street 8th Floor
City:<\/strong> New York
State:<\/strong> New York 10005
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.polarismarketresearch.com\/industry-analysis\/platinum-based-cancer-drugs-market<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Polaris Market Research The global platinum based Cancer drugs market size was valued at USD 1,310.3 Million in 2018 and is expected to exhibit a CAGR of 4.1% from 2019 – 2026 according to a report published by Polaris Market … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,412,406,416],"tags":[],"class_list":["post-437718","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-News-Current-Affairs","category-Pharmaceuticals-Biotech","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/437718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=437718"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/437718\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=437718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=437718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=437718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}